Budesonide-Loaded Hyaluronic Acid Nanoparticles for Targeted Delivery to the Inflamed Intestinal Mucosa in a Rodent Model of Colitis

Table 1

Characterization of budesonide-loaded HA–NPs ( = 3; data are expressed as mean ± SD).

NPs characterization
	Size (nm)	Zeta potential (mV)	PdI	BDS content (Wt. %)^a	Encapsulation efficiency (%)^b
Blank HA NPs	177 ± 6	- 19.66 ± 0.74	0.22 ± 0.03	—	—
BDS loaded HANPs	266 ± 16	- 3.98 ± 0.46	0.29 ± 0.08	9.3 ± 0.45	18.6

^aCalculated by dividing the encapsulated BDS with the predetermined amount of BDS loaded HA–NPs. ^bCalculated by dividing the encapsulated BDS with initial BDS amount.